Annual Conference & Webinar Schedule

To learn more about NP Thyroid®, please visit the Acella Pharmaceuticals booth at the events listed below. Acella also invites you to attend our product theater sessions.

By clicking "Register" below, you will be redirected to the event host’s website, where you can complete your registration.

JANUARY

Clinical Diabetes & Endocrinology Institute Annual
(CDEI)

January 23-26, 2026 – Vail, CO

Table #: 28

APRIL

A4M Spring

April 10-12, 2026 – West Palm Beach, FL

Booth #: 247

American Association of Clinical Endocrinology Annual Meeting (AACE)

April 22-24, 2026 – Las Vegas, NV

Booth #: 108

Product Theater

Thursday, April 23 at 2:30-3:15 PM ET

Title

TBD

MAY

American Academy of Physician Associates 2026 (AAPA)

May 15-19, 2026 – New Orleans, LA

Booth #: TBD

Product Theater

Saturday, May 16 at 11:45 AM-12:45 PM CT with speakers Jaime Ginney, PA-C and Olivia Crimmins,
PA-C

Title

TBD

AIC 2026 - IFM's Functional Medicine Conference

May 27-30, 2026 – San Diego, CA

Booth #: 722

Product Theater

Friday, May 29 at 6:45-7:45 AM PT with speaker Angela Mazza, DO

Title

TBD

JUNE

Endocrine Society's Annual Meeting 2026 (ENDO)

June 13-16, 2026 – Chicago, IL

Booth #: TBD

Product Theater

Saturday, June 13 at 12:30-1:30 PM CT

Title

TBD

American Association of Nurse Practitioners (AANP)

June 23-28, 2026 – Las Vegas, Nevada

Booth #: TBD

Product Theater

Wednesday, June 24 at 11:45 AM-1:00 PM PT

Title

TBD

September

Texas Nurse Practitioners Annual Fall Conference (TNP)

September 24-27, 2026 – San Antonio, Texas

Booth #: TBD

Product Theater

Friday, September 25 at 7:45- 8:45 AM CT

Title

TBD

October

New York Nurse Practitioners Association (NPA)

October 1-4, 2026 – Niagara Falls, NY

Booth #: TBD

Mid-Atlantic Society of Endocrinologists 2025 Annual Meeting (MASE)

TBD – Hyattesville, MD

Booth #: TBD

Michigan Council of Nurse Practitioners Annual Conference (MICNP)

TBD – Michigan

Booth #: TBD

November

American Thyroid Association (ATA)

November 4-7, 2026 – Philadelphia, PA

Booth #: TBD

December

A4M Winter

December 11-13, 2026 – Las Vegas, NV

Booth #: 474

You Are About To Leave This Website

By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply.

Continue

You Are About To Leave This Website

By clicking continue, this link will take you to a website to which Alora Pharmaceuticals’ Policies & Terms of Use do not apply. Alora and its subsidiaries do not control the content or accuracy of third-party websites and assume no responsibility for their use.

Continue

Note that DTE products, including NP Thyroid®, have not been reviewed by the FDA for safety or efficacy.

IMPORTANT RISK INFORMATION, INCLUDING BOXED WARNING & INDICATIONS
Important Risk Information

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
  • In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
  • Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
  • The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
  • Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
  • In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
  • Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
  • Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
  • NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.

Indications

NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.

NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.

Revised 10/2023